Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With…

GanglioneuroblastomaChildren's healthProcedureDrugBiologicalRadiationPhase 3

What this study is

This phase III trial studies iobenguane I-131 or lorlatinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Lorlatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or lorlatinib and standard therapy may work better compared to lorlatinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

What's being tested

Autologous Hematopoietic Stem Cell Transplantation
Intervention · PROCEDURE
Undergo autologous HSCT
Biospecimen Collection
Intervention · PROCEDURE
Undergo blood sample collection
Bone Marrow Aspiration and Biopsy
Intervention · PROCEDURE
Undergo bone marrow aspiration and biopsy
Busulfan
Intervention · DRUG
Carboplatin
Intervention · DRUG
Cisplatin
Intervention · DRUG
Computed Tomography
Intervention · PROCEDURE
Undergo CT scan
Cyclophosphamide
Intervention · DRUG
Dexrazoxane Hydrochloride
Intervention · DRUG
Dinutuximab
Intervention · BIOLOGICAL
Doxorubicin Hydrochloride
Intervention · DRUG
Echocardiography Test
Intervention · PROCEDURE
Undergo echocardiography
Etoposide Phosphate
Intervention · DRUG
External Beam Radiation Therapy
Intervention · RADIATION
Undergo EBRT
Iobenguane I-123
Intervention · RADIATION
Given 123 I-MIBG
Iobenguane I-131
Intervention · RADIATION
Isotretinoin
Intervention · DRUG
Lorlatinib
Intervention · DRUG
Magnetic Resonance Imaging
Intervention · PROCEDURE
Undergo MRI
Melphalan Hydrochloride
Intervention · DRUG
Multigated Acquisition Scan
Intervention · PROCEDURE
Undergo MUGA scan
Positron Emission Tomography
Intervention · PROCEDURE
Undergo PET scan
Sargramostim
Intervention · BIOLOGICAL
Given SC
Therapeutic Conventional Surgery
Intervention · PROCEDURE
Undergo standard of care surgery
Thiotepa
Intervention · DRUG
Topotecan Hydrochloride
Intervention · DRUG
Vincristine Sulfate
Intervention · DRUG

All of Busulfan, Carboplatin, Cisplatin, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Etoposide Phosphate, Iobenguane I-131, Melphalan Hydrochloride, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate

Given IV

Both Isotretinoin and Lorlatinib

Given PO

Study details

Official title: A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
Sponsor: Children's Oncology Group
Conditions: Ganglioneuroblastoma · Ganglioneuroblastoma, Nodular · Neuroblastoma
Enrolling: 750 people
Starts: 2018-05-14
Est. completion: 2030-09-30
Design: Open-label, randomized, parallel groups, Phase 3
Record: View on ClinicalTrials.gov ↗

Who can join

Age 365 Days – 30 YearsSex ALLHealthy volunteers Not accepted

You may qualify if

FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patients must be enrolled on ANBL00B1 (NCT00904241) or APEC14B1 (NCT02402244) prior to enrollment on ANBL1531 (NCT03126916)
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patient must be >= 365 days and =< 30 years of age at diagnosis
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patients must have a diagnosis of neuroblastoma or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites; the following disease groups are eligible:; Patients with International Neuroblastoma Risk Group (INRG) stage M disease are eligible if found to have either of the following features:; MYCN amplification (> 4-fold increase in MYCN signals as compared to reference signals), regardless of additional biologic features; OR; Age > 547 days regardless of biologic features; Patients with INRG stage MS disease with MYCN amplification; Patients with INRG stage L2 disease with MYCN amplification; Patients > 547 days of age initially diagnosed with INRG stage L1, L2 or MS disease who progressed to stage M without prior chemotherapy may enroll within 4 weeks of progression to stage M; Patients >= 365 days of age initially diagnosed with MYCN amplified INRG stage L1 disease who progress to stage M without systemic therapy may enroll within 4 weeks of progression to stage M
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patients initially recognized to have high-risk disease must have had no prior systemic therapy (other than topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing); patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high risk disease but subsequently found to meet the criteria will also be eligible; patients who receive localized emergency radiation to sites of life-threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis will be eligible
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/sex as follows:; 1 to < 2 years: male = 0.6; female = 0.6; 2 to < 6 years: male = 0.8; female = 0.8; 6 to < 10 years: male = 1; female = 1; 10 to < 13 years: male = 1.2; female = 1.2; 13 to < 16 years: male = 1.5; female = 1.4; >= 16 years: male = 1.7; female = 1.4
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Total bilirubin =< 1.5 x upper limit of normal (ULN) for age, and
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) < 10 x ULN; for the purposes of this study, ULN for SGPT (ALT) is 45
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Shortening fraction of >= 27% by echocardiogram, or ejection fraction of > 50% by echocardiogram or radionuclide angiogram
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: No known contraindication to peripheral blood stem cell (PBSC) collection; examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): See ANBL2131 (NCT06172296) protocol for eligible high-risk neuroblastoma diagnoses
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): In addition, all patients transferring from ANBL2131 (NCT06172296) to ANBL1531 (NCT03126916) Arm E must have tumors with an ALK aberration
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Given the lack of data with lorlatinib in infant populations, patients transferring from ANBL2131 (NCT06172296) to ANBL1531 (NCT03126916) must be > 1 year of age at time of transfer to ANBL1531 (NCT03126916). Patients < 1 year of age found to have a qualifying ALK alteration as part of ANBL2131 (NCT06172296) may continue to participate in ANBL2131 (NCT06172296)
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients initially recognized to have high-risk disease must have received no more than one cycle of topotecan/cyclophosphamide either after enrollment to ANBL2131 (NCT06172296) or started emergently prior to enrollment to ANBL2131 (NCT06172296)
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients may have received up to one cycle of intermediate risk chemotherapy prior to initial enrollment to ANBL2131 (NCT06172296)
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients may have received localized emergency radiation to sites of life-threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): In order to facilitate patient transfer and ensure timely distribution of lorlatinib, there are no blood count requirements to meet at time of transfer from ANBL2131 (NCT06172296) to ANBL1531 ((NCT03126916) Arm E. Note the blood count criteria that must be met prior to start of Induction cycle 2 on Arm E. Lorlatinib therapy should start no sooner than day 1 of Induction cycle 2
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): No known irreversible grade 2 or greater atrioventricular (AV) block
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Due the potential psychiatric risks from lorlatinib, patients should not have a personal history of a serious psychiatric disorder requiring pharmacologic intervention or severe enough to be considered life-threatening
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution deems feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure

You can't join if

FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patients with INRG stage L2 tumors without amplification of MYCN regardless of tumor histology (may meet criteria for high risk classification but are not eligible for this trial)
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patients with bone marrow failure syndromes
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Patients for whom targeted radiopharmaceutical therapy would be contraindicated due to underlying medical disorders
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs; a pregnancy test is required for female patients of childbearing potential
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Lactating females who plan to breastfeed their infants
FOR PATIENTS ENROLLING TO ANBL1531 (NCT03126916) WITHOUT PRIOR ANBL2131 (NCT06172296) ENROLLMENT: Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients who have previously received treatment with lorlatinib or other ALK inhibitor
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients who have undergone treatment arm randomization callback or started induction cycle 2 on ANBL2131 (NCT06172296)
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients who have an INRG Stage L2 tumor without amplification of MYCN regardless of tumor histology (may meet criteria for high risk classification but are not eligible for this trial)
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Patients with bone marrow failure syndromes
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required for female patients of childbearing potential
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Lactating females who plan to breastfeed their infants
PATIENTS WITH TUMORS HARBORING ALK ALTERATIONS TRANSFERRING TO ANBL1531 (NCT03126916) ARM E FROM ANBL2131 (NCT06172296) (EFFECTIVE WITH AMENDMENT 13C): Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation

Study locations (161)

152 open

Children's Hospital of Alabama
Birmingham, Alabama, United States
- Contact205-638-9285 oncologyresearch@peds.uab.edu
- Elizabeth D. Alva · Principal investigator
Recruiting
Phoenix Childrens Hospital
Phoenix, Arizona, United States
- Contact602-546-0920
- Francis K. Eshun · Principal investigator
Recruiting
Arkansas Children's Hospital
Little Rock, Arkansas, United States
- Contact501-364-7373
- David L. Becton · Principal investigator
Recruiting
Kaiser Permanente Downey Medical Center
Downey, California, United States
- Contact626-564-3455
- Robert M. Cooper · Principal investigator
Recruiting
Loma Linda University Medical Center
Loma Linda, California, United States
- Contact909-558-4050
- Albert Kheradpour · Principal investigator
Recruiting
Children's Hospital Los Angeles
Los Angeles, California, United States
- Contact323-361-4110
- Araz Marachelian · Principal investigator
Recruiting
Mattel Children's Hospital UCLA
Los Angeles, California, United States
- Contact310-825-6708
- Satiro N. De Oliveira · Principal investigator
Recruiting
Valley Children's Hospital
Madera, California, United States
- Contact559-353-3000 Research@valleychildrens.org
- Ruetima Titapiwatanakun · Principal investigator
Recruiting
Kaiser Permanente-Oakland
Oakland, California, United States
- Contact877-642-4691 Kpoct@kp.org
- Aarati V. Rao · Principal investigator
Recruiting
Children's Hospital of Orange County
Orange, California, United States
- Contact714-509-8646 oncresearch@choc.org
- Elyssa M. Rubin · Principal investigator
Recruiting
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, United States
- Contact800-694-0012 ccto-office@stanford.edu
- Jay Michael S. Balagtas · Principal investigator
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
- Contact916-734-3089
- Marcio H. Malogolowkin · Principal investigator
Recruiting
Rady Children's Hospital - San Diego
San Diego, California, United States
- Contact858-966-5934
- William D. Roberts · Principal investigator
Recruiting
Naval Medical Center -San Diego
San Diego, California, United States
- Contact619-532-8712
- Yoko T. Udaka · Principal investigator
Recruiting
UCSF Medical Center-Mission Bay
San Francisco, California, United States
- Contact877-827-3222 cancertrials@ucsf.edu
- Kieuhoa T. Vo · Principal investigator
Recruiting
Children's Hospital Colorado
Aurora, Colorado, United States
- Contact303-764-5056 josh.b.gordon@nsmtp.kp.org
- Margaret E. Macy · Principal investigator
Recruiting
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
Denver, Colorado, United States
- Contact303-832-2344 PSGResearchSharedMailbox@HCAHealthcare.com
- Florence Choo · Principal investigator
Recruiting
Connecticut Children's Medical Center
Hartford, Connecticut, United States
- Contact860-545-9981
- Michael S. Isakoff · Principal investigator
Recruiting
Yale University
New Haven, Connecticut, United States
- Contact203-785-5702 canceranswers@yale.edu
- Farzana Pashankar · Principal investigator
Recruiting
Alfred I duPont Hospital for Children
Wilmington, Delaware, United States
- Contact302-651-5572 Allison.bruce@nemours.org
- Vibhuti Agarwal · Principal investigator
Recruiting
Children's National Medical Center
Washington D.C., District of Columbia, United States
- Contact202-476-2800 OncCRC_OnCall@childrensnational.org
- Jeffrey S. Dome · Principal investigator
Recruiting
Golisano Children's Hospital of Southwest Florida
Fort Myers, Florida, United States
- Contact239-343-5333 molly.arnstrom@leehealth.org
- Emad K. Salman · Principal investigator
Recruiting
UF Health Cancer Institute - Gainesville
Gainesville, Florida, United States
- Contact352-273-8010 cancer-center@ufl.edu
- Brian Stover · Principal investigator
Recruiting
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, United States
- Contact954-265-1847 OHR@mhs.net
- Iftikhar Hanif · Principal investigator
Recruiting
Nemours Children's Clinic-Jacksonville
Jacksonville, Florida, United States
- Contact302-651-5572 Allison.bruce@nemours.org
- Vibhuti Agarwal · Principal investigator
Recruiting
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, United States
- Contact305-243-2647
- Meghan McCormick · Principal investigator
Recruiting
Nicklaus Children's Hospital
Miami, Florida, United States
- Contact888-624-2778
- Maggie E. Fader · Principal investigator
Recruiting
AdventHealth Orlando
Orlando, Florida, United States
- Contact407-303-2090 FH.Cancer.Research@flhosp.org
- Fouad M. Hajjar · Principal investigator
Recruiting
Nemours Children's Hospital
Orlando, Florida, United States
- Contact302-651-5572 Allison.bruce@nemours.org
- Vibhuti Agarwal · Principal investigator
Recruiting
Johns Hopkins All Children's Hospital
St. Petersburg, Florida, United States
- Contact727-767-4784 Ashley.Repp@jhmi.edu
- Jennifer B. Dean · Principal investigator
Recruiting
Saint Mary's Medical Center
West Palm Beach, Florida, United States
- Contact561-822-4745
- Matthew D. Ramirez · Principal investigator
Recruiting
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, Georgia, United States
- Contact404-785-0232 Olivia.Floyd@choa.org
- William T. Cash · Principal investigator
Recruiting
Memorial Health University Medical Center
Savannah, Georgia, United States
- Contact912-350-7887 Lorraine.OHara@hcahealthcare.com
- Andrew L. Pendleton · Principal investigator
Recruiting
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, United States
- Contact808-983-6090
- Wade T. Kyono · Principal investigator
Recruiting
Saint Luke's Cancer Institute - Boise
Boise, Idaho, United States
- Contact208-381-2774 eslinget@slhs.org
- Martha M. Pacheco · Principal investigator
Recruiting
Lurie Children's Hospital-Chicago
Chicago, Illinois, United States
- Contact773-880-4562
- Elizabeth A. Sokol · Principal investigator
Recruiting
University of Illinois
Chicago, Illinois, United States
- Contact312-355-3046
- Dipti S. Dighe · Principal investigator
Recruiting
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, United States
- Contact773-702-8222 cancerclinicaltrials@bsd.uchicago.edu
- Susan L. Cohn · Principal investigator
Recruiting
Advocate Children's Hospital-Oak Lawn
Oak Lawn, Illinois, United States
- Contact847-723-7570
- Rebecca E. McFall · Principal investigator
Recruiting
Advocate Children's Hospital-Park Ridge
Park Ridge, Illinois, United States
- Contacthelpdesk@childrensoncologygroup.org
- Rebecca E. McFall · Principal investigator
Recruiting
Saint Jude Midwest Affiliate
Peoria, Illinois, United States
- Contact888-226-4343
- Prerna Kumar · Principal investigator
Recruiting
Southern Illinois University School of Medicine
Springfield, Illinois, United States
- Contact217-545-7929
- Gregory P. Brandt · Principal investigator
Recruiting
Riley Hospital for Children
Indianapolis, Indiana, United States
- Contact800-248-1199
- Sandeep Batra · Principal investigator
Recruiting
Blank Children's Hospital
Des Moines, Iowa, United States
- Contact515-241-8912 samantha.mallory@unitypoint.org
- Samantha L. Mallory · Principal investigator
Recruiting
University of Iowa/Holden Comprehensive Cancer Center
Iowa City, Iowa, United States
- Contact800-237-1225
- David S. Dickens · Principal investigator
Recruiting
University of Kentucky/Markey Cancer Center
Lexington, Kentucky, United States
- Contact859-257-3379
- James T. Badgett · Principal investigator
Recruiting
Children's Hospital New Orleans
New Orleans, Louisiana, United States
- Contact504-894-5377
- Maria C. Velez-Yanguas · Principal investigator
Recruiting
Ochsner Medical Center Jefferson
New Orleans, Louisiana, United States
- Contact504-842-8084 Elisemarie.curry@ochsner.org
- Craig Lotterman · Principal investigator
Recruiting
Eastern Maine Medical Center
Bangor, Maine, United States
- Contact207-973-4274
- Daniel L. Callaway · Principal investigator
Recruiting
Maine Children's Cancer Program
Scarborough, Maine, United States
- Contact207-396-8670 clinicalresearch@mainehealth.org
- Eric C. Larsen · Principal investigator
Recruiting
Sinai Hospital of Baltimore
Baltimore, Maryland, United States
- Contact410-601-9083
- Jason M. Fixler · Principal investigator
Recruiting
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Contact410-955-8804 jhcccro@jhmi.edu
- Allen R. Chen · Principal investigator
Recruiting
Walter Reed National Military Medical Center
Bethesda, Maryland, United States
- Contact301-319-2100
- Allen I. Stering · Principal investigator
Recruiting
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, United States
- Contact877-726-5130
- Suzanne Shusterman · Principal investigator
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Contact877-442-3324
- Suzanne Shusterman · Principal investigator
Recruiting
C S Mott Children's Hospital
Ann Arbor, Michigan, United States
- Contact800-865-1125
- Rajen Mody · Principal investigator
Recruiting
Children's Hospital of Michigan
Detroit, Michigan, United States
- Contacthelpdesk@childrensoncologygroup.org
- Roland L. Chu · Principal investigator
Recruiting
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States
- Contact616-391-1230 crcwm-regulatory@crcwm.org
- Kathleen Y. Butler · Principal investigator
Recruiting
Bronson Methodist Hospital
Kalamazoo, Michigan, United States
- Contact616-391-1230 crcwm-regulatory@crcwm.org
- Kathleen Y. Butler · Principal investigator
Recruiting
Corewell Health Children's
Royal Oak, Michigan, United States
- Contact248-551-7695
- Marie V. Nelson · Principal investigator
Recruiting
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota, United States
- Contact612-813-5913 pauline.mitby@childrensmn.org
- Michael K. Richards · Principal investigator
Recruiting
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States
- Contact612-624-2620
- Robin L. Williams · Principal investigator
Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, United States
- Contact855-776-0015
- Wendy Allen-Rhoades · Principal investigator
Recruiting
University of Mississippi Medical Center
Jackson, Mississippi, United States
- Contact601-815-6700
- Betty L. Herrington · Principal investigator
Recruiting
University of Missouri Children's Hospital
Columbia, Missouri, United States
- Contact573-882-1960 snwq62@health.missouri.edu
- Barbara A. Gruner · Principal investigator
Recruiting
Children's Mercy Hospitals and Clinics
Kansas City, Missouri, United States
- Contact816-302-6808 COGResearchGroup@cmh.edu
- Keith J. August · Principal investigator
Recruiting
Washington University School of Medicine
St Louis, Missouri, United States
- Contact800-600-3606 info@siteman.wustl.edu
- Frederick S. Huang · Principal investigator
Recruiting
Mercy Hospital Saint Louis
St Louis, Missouri, United States
- Contact314-251-7066
- Robin D. Hanson · Principal investigator
Recruiting
Children's Hospital and Medical Center of Omaha
Omaha, Nebraska, United States
- Contact402-955-3949
- Jill C. Beck · Principal investigator
Recruiting
University of Nebraska Medical Center
Omaha, Nebraska, United States
- Contact402-559-6941 unmcrsa@unmc.edu
- Jill C. Beck · Principal investigator
Recruiting
University Medical Center of Southern Nevada
Las Vegas, Nevada, United States
- Contact702-384-0013 research@sncrf.org
- Alan K. Ikeda · Principal investigator
Recruiting
Sunrise Hospital and Medical Center
Las Vegas, Nevada, United States
- Contact702-384-0013 research@sncrf.org
- Alan K. Ikeda · Principal investigator
Recruiting
Alliance for Childhood Diseases/Cure 4 the Kids Foundation
Las Vegas, Nevada, United States
- Contact702-384-0013 research@sncrf.org
- Alan K. Ikeda · Principal investigator
Recruiting
Summerlin Hospital Medical Center
Las Vegas, Nevada, United States
- Contact702-384-0013 research@sncrf.org
- Alan K. Ikeda · Principal investigator
Recruiting
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Lebanon, New Hampshire, United States
- Contact800-639-6918 cancer.research.nurse@dartmouth.edu
- Angela Ricci · Principal investigator
Recruiting
Hackensack University Medical Center
Hackensack, New Jersey, United States
- Contact551-996-2897
- Katharine Offer · Principal investigator
Recruiting
Morristown Medical Center
Morristown, New Jersey, United States
- Contact973-971-5900
- Kathryn L. Laurie · Principal investigator
Recruiting
Saint Peter's University Hospital
New Brunswick, New Jersey, United States
- Contact732-745-8600 ext. 6163 kcovert@saintpetersuh.com
- Nibal A. Zaghloul · Principal investigator
Recruiting
Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
New Brunswick, New Jersey, United States
- Contact732-235-8675
- Nehal S. Parikh · Principal investigator
Recruiting
Newark Beth Israel Medical Center
Newark, New Jersey, United States
- Contact973-926-7230 Christine.Kosmides@rwjbh.org
- Teena Bhatla · Principal investigator
Recruiting
Saint Joseph's Regional Medical Center
Paterson, New Jersey, United States
- Contact973-754-2207 HallL@sjhmc.org
- Alissa Kahn · Principal investigator
Recruiting
University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- Contact505-925-0348 HSC-ClinicalTrialInfo@salud.unm.edu
- Jessica M. Valdez · Principal investigator
Recruiting
Albany Medical Center
Albany, New York, United States
- Contact518-262-5513
- Lauren R. Weintraub · Principal investigator
Recruiting
Maimonides Medical Center
Brooklyn, New York, United States
- Contact718-765-2500
- Mahmut Y. Celiker · Principal investigator
Recruiting
Roswell Park Cancer Institute
Buffalo, New York, United States
- Contact800-767-9355 askroswell@roswellpark.org
- Clare J. Twist · Principal investigator
Recruiting
NYU Langone Hospital - Long Island
Mineola, New York, United States
- Contact212-263-4432 cancertrials@nyulangone.org
- Chana L. Glasser · Principal investigator
Recruiting
The Steven and Alexandra Cohen Children's Medical Center of New York
New Hyde Park, New York, United States
- Contact718-470-3460
- Julie I. Krystal · Principal investigator
Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, United States
- ContactCancerTrials@nyulangone.org
- Elizabeth A. Raetz · Principal investigator
Recruiting
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, New York, United States
- Contact212-342-5162 cancerclinicaltrials@cumc.columbia.edu
- Nobuko Hijiya · Principal investigator
Recruiting
University of Rochester
Rochester, New York, United States
- Contact585-275-5830
- Jeffrey R. Andolina · Principal investigator
Recruiting
Stony Brook University Medical Center
Stony Brook, New York, United States
- Contact800-862-2215
- Laura E. Hogan · Principal investigator
Recruiting
State University of New York Upstate Medical University
Syracuse, New York, United States
- Contact315-464-5476
- Melanie A. Comito · Principal investigator
Recruiting
Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
- Contact718-379-6866 eskwak@montefiore.org
- Alice Lee · Principal investigator
Recruiting
New York Medical College
Valhalla, New York, United States
- Contact914-594-3794
- Jessica C. Hochberg · Principal investigator
Recruiting
Mission Hospital
Asheville, North Carolina, United States
- Contact828-213-7055 NCDV.ResearchRegulatory@HCAHealthcare.com
- Douglas J. Scothorn · Principal investigator
Recruiting
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, United States
- Contact877-668-0683 cancerclinicaltrials@med.unc.edu
- Thomas B. Alexander · Principal investigator
Recruiting
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, United States
- Contact800-804-9376
- Joel A. Kaplan · Principal investigator
Recruiting
Duke University Medical Center
Durham, North Carolina, United States
- Contact888-275-3853
- Jessica M. Sun · Principal investigator
Recruiting
East Carolina University
Greenville, North Carolina, United States
- Contact252-744-1015 eubankss@ecu.edu
- Andrea R. Whitfield · Principal investigator
Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
- Contact336-713-6771
- Thomas W. McLean · Principal investigator
Recruiting
Sanford Broadway Medical Center
Fargo, North Dakota, United States
- Contact701-323-5760 OncologyClinicalTrialsFargo@sanfordhealth.org
- Samuel J. Milanovich · Principal investigator
Recruiting
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
- Contact513-636-2799 cancer@cchmc.org
- Robin E. Norris · Principal investigator
Recruiting
Rainbow Babies and Childrens Hospital
Cleveland, Ohio, United States
- Contact216-844-5437
- Duncan S. Stearns · Principal investigator
Recruiting
Cleveland Clinic Foundation
Cleveland, Ohio, United States
- Contact866-223-8100 TaussigResearch@ccf.org
- Matteo M. Trucco · Principal investigator
Recruiting
Nationwide Children's Hospital
Columbus, Ohio, United States
- Contact614-722-6039 Melinda.Triplet@nationwidechildrens.org
- Mark A. Ranalli · Principal investigator
Recruiting
Dayton Children's Hospital
Dayton, Ohio, United States
- Contact800-228-4055
- Jordan M. Wright · Principal investigator
Recruiting
ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
Toledo, Ohio, United States
- Contact419-824-1842 PCIOncResearch@promedica.org
- Jamie L. Dargart · Principal investigator
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
- Contact405-271-8777 ou-clinical-trials@ouhsc.edu
- Rene Y. McNall-Knapp · Principal investigator
Recruiting
Legacy Emanuel Children's Hospital
Portland, Oregon, United States
- Contact503-413-2560
- Jason M. Glover · Principal investigator
Recruiting
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, United States
- Contact610-402-9543 Morgan_M.Horton@lvhn.org
- Jacob A. Troutman · Principal investigator
Recruiting
Geisinger Medical Center
Danville, Pennsylvania, United States
- Contact570-271-5251 HemonCCTrials@geisinger.edu
- Jagadeesh Ramdas · Principal investigator
Recruiting
Penn State Children's Hospital
Hershey, Pennsylvania, United States
- Contact717-531-6012
- Lisa M. McGregor · Principal investigator
Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
- Contact267-425-5544 CancerTrials@email.chop.edu
- Rochelle Bagatell · Principal investigator
Recruiting
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
- Contact412-692-8570 jean.tersak@chp.edu
- Jean M. Tersak · Principal investigator
Recruiting
Rhode Island Hospital
Providence, Rhode Island, United States
- Contact401-444-1488
- Bradley DeNardo · Principal investigator
Recruiting
Medical University of South Carolina
Charleston, South Carolina, United States
- Contact843-792-9321 hcc-clinical-trials@musc.edu
- Jacqueline M. Kraveka · Principal investigator
Recruiting
Prisma Health Richland Hospital
Columbia, South Carolina, United States
- Contact864-522-4317 Kim.Williams3@prismahealth.org
- Stuart L. Cramer · Principal investigator
Recruiting
BI-LO Charities Children's Cancer Center
Greenville, South Carolina, United States
- Contact864-522-4317 Kim.Williams3@prismahealth.org
- Aniket Saha · Principal investigator
Recruiting
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, United States
- Contact605-312-3320 OncologyClinicalTrialsSF@SanfordHealth.org
- Kayelyn J. Wagner · Principal investigator
Recruiting
East Tennessee Childrens Hospital
Knoxville, Tennessee, United States
- Contact865-541-8266
- Susan E. Spiller · Principal investigator
Recruiting
Saint Jude Children's Research Hospital
Memphis, Tennessee, United States
- Contact888-226-4343 referralinfo@stjude.org
- Sara M. Federico · Principal investigator
Recruiting
The Children's Hospital at TriStar Centennial
Nashville, Tennessee, United States
- Contact615-342-1919
- Clinton M. Carroll · Principal investigator
Recruiting
Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee, United States
- Contact800-811-8480
- Daniel J. Benedetti · Principal investigator
Recruiting
Dell Children's Medical Center of Central Texas
Austin, Texas, United States
- Contact512-628-1902 TXAUS-DL-SFCHemonc.research@ascension.org
- Shannon M. Cohn · Principal investigator
Recruiting
Driscoll Children's Hospital
Corpus Christi, Texas, United States
- Contact361-694-5311 Crystal.DeLosSantos@dchstx.org
- Nkechi I. Mba · Principal investigator
Recruiting
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas, United States
- Contact214-648-7097 canceranswerline@UTSouthwestern.edu
- Tanya C. Watt · Principal investigator
Recruiting
El Paso Children's Hospital
El Paso, Texas, United States
- Contact915-298-5444 ranjan.bista@ttuhsc.edu
- Benjamin Carcamo · Principal investigator
Recruiting
Cook Children's Medical Center
Fort Worth, Texas, United States
- Contact682-885-2103 CookChildrensResearch@cookchildrens.org
- Chelsee Greer · Principal investigator
Recruiting
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, United States
- Contact713-798-1354 burton@bcm.edu
- Jennifer H. Foster · Principal investigator
Recruiting
Covenant Children's Hospital
Lubbock, Texas, United States
- Contact806-725-8657 mbisbee@providence.org
- Kishor M. Bhende · Principal investigator
Recruiting
UMC Cancer Center / UMC Health System
Lubbock, Texas, United States
- Contact806-775-8590
- Erin K. Barr · Principal investigator
Recruiting
Children's Hospital of San Antonio
San Antonio, Texas, United States
- Contact210-704-2894 bridget.medina@christushealth.org
- Julie Voeller · Principal investigator
Recruiting
Methodist Children's Hospital of South Texas
San Antonio, Texas, United States
- Contact210-575-6240 Vinod.GidvaniDiaz@hcahealthcare.com
- Jose M. Esquilin · Principal investigator
Recruiting
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
- Contact210-450-3800 phoresearchoffice@uthscsa.edu
- Anne-Marie R. Langevin · Principal investigator
Recruiting
Primary Children's Hospital
Salt Lake City, Utah, United States
- Contact801-585-5270
- Matthew Dietz · Principal investigator
Recruiting
University of Vermont and State Agricultural College
Burlington, Vermont, United States
- Contact802-656-8990 rpo@uvm.edu
- Jessica L. Heath · Principal investigator
Recruiting
Seattle Children's Hospital
Seattle, Washington, United States
- Contact866-987-2000
- Sarah E. Leary · Principal investigator
Recruiting
Providence Sacred Heart Medical Center and Children's Hospital
Spokane, Washington, United States
- Contact800-228-6618 HopeBeginsHere@providence.org
- Judy L. Felgenhauer · Principal investigator
Recruiting
Mary Bridge Children's Hospital and Health Center
Tacoma, Washington, United States
- Contact253-403-1461 research@multicare.org
- Robert G. Irwin · Principal investigator
Recruiting
Madigan Army Medical Center
Tacoma, Washington, United States
- Contact253-968-6144 melissa.a.forouhar.mil@health.mil
- Melissa A. Forouhar · Principal investigator
Recruiting
West Virginia University Healthcare
Morgantown, West Virginia, United States
- Contact304-293-7374 cancertrialsinfo@hsc.wvu.edu
- Ashley E. Meyer · Principal investigator
Recruiting
Saint Vincent Hospital Cancer Center Green Bay
Green Bay, Wisconsin, United States
- Contact920-433-8889 WI_research_admin@hshs.org
- Catherine A. Long · Principal investigator
Recruiting
University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, United States
- Contact800-622-8922 clinicaltrials@cancer.wisc.edu
- Margo L. Hoover-Regan · Principal investigator
Recruiting
Marshfield Medical Center-Marshfield
Marshfield, Wisconsin, United States
- Contact800-782-8581 oncology.clinical.trials@marshfieldresearch.org
- Michelle A. Manalang · Principal investigator
Recruiting
Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
- Contact414-955-4727 MACCCTO@mcw.edu
- Angela Steineck · Principal investigator
Recruiting
Tufts Children's Hospital
Boston, Massachusetts, United States
Active, not recruiting
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Active, not recruiting
Henry Ford Health Saint John Hospital
Detroit, Michigan, United States
Active, not recruiting
Michigan State University
East Lansing, Michigan, United States
Suspended
Medical City Dallas Hospital
Dallas, Texas, United States
Active, not recruiting
VCU Massey Comprehensive Cancer Center
Richmond, Virginia, United States
Active, not recruiting

10 sites outside the US

CancerCare Manitoba
Winnipeg, Manitoba, Canada
- Contact866-561-1026 ctu_web@cancercare.mb.ca
- Stephanie M. Villeneuve · Principal investigator
Recruiting
Janeway Child Health Centre
St. John's, Newfoundland and Labrador, Canada
- Contact709-777-8727 beverlyj.mitchell@easternhealth.ca
- Lisa A. Goodyear · Principal investigator
Recruiting
IWK Health Centre
Halifax, Nova Scotia, Canada
- Contact902-470-8520 Research@iwk.nshealth.ca
- Craig Erker · Principal investigator
Recruiting
Kingston Health Sciences Centre
Kingston, Ontario, Canada
- Contact613-549-6666 cc-clinicaltrials@kgh.kari.net
- Laura Wheaton · Principal investigator
Recruiting
Children's Hospital
London, Ontario, Canada
- Contact519-685-8306
- Shayna M. Zelcer · Principal investigator
Recruiting
Children's Hospital of Eastern Ontario
Ottawa, Ontario, Canada
- Contact613-737-7600
- Donna L. Johnston · Principal investigator
Recruiting
Hospital for Sick Children
Toronto, Ontario, Canada
- Contact416-813-7654 ask.CRS@sickkids.ca
- Daniel A. Morgenstern · Principal investigator
Recruiting
British Columbia Children's Hospital
Vancouver, British Columbia, Canada
Suspended
McMaster Children's Hospital at Hamilton Health Sciences
Hamilton, Ontario, Canada
Suspended
HIMA San Pablo Oncologic Hospital
Caguas, Puerto Rico
Active, not recruiting

Adding iobenguane I-131 or lorlatinib to intensive therapy for high-risk neuroblastoma

What this study is

What's being tested

Study details

Who can join

Monitoring & Endpoints

Study locations (161)

Study team

Children's Oncology Group

Steven G DuBois

Frequently asked questions